View More Recent Stories
-
Firms face COVID-level uncertainty amid Trump tariffs - Morgan Stanley
-
Stifel Reiterates Buy Rating on Zoetis Inc. (ZTS)
-
Zoetis Inc. (ZTS) PT Lowered to $200 at BTIG
-
Zoetis (ZTS) Receives Conditional License from USDA for Avian Influenza Vaccine
-
Zoetis (ZTS) Tops Q4 EPS by 2c; misses on guidance
-
BTIG Reiterates Buy Rating on Zoetis Inc. (ZTS)
-
Zoetis (ZTS) Declares $0.50 Quarterly Dividend; 1.1% Yield
-
Zoetis (ZTS) Announces U.S. Label Update for Librela, a Treatment to Control Canine Osteoarthritis (OA) Pain
-
Stifel Reiterates Buy Rating on Zoetis Inc. (ZTS)
-
Zoetis Inc. (ZTS) PT Lowered to $180 at Stifel Reflecting Lower Librela Estimates
-
Zoetis (ZTS) Appoints Jamie Brannan as Chief Commercial Officer
-
Zoetis (ZTS) Tops Q3 EPS by 12c, Offers Guidance
-
Zoetis (ZTS) call put ratio 8.7 calls to 1 put with focus on November 185 and 200 calls into quarter results
-
Zoetis (ZTS) November 180 straddle priced into quarter results
-
Zoetis (ZTS) Declares $0.432 Quarterly Dividend; 0.9% Yield
-
TD Cowen Reiterates Buy Rating on Zoetis Inc. (ZTS)
-
Zoetis Inc. (ZTS) PT Raised to $225 at BTIG
-
Zoetis (ZTS) Tops Q2 EPS by 7c. raises guidance
-
Zoetis Inc. (ZTS) PT Raised to $200 at Stifel
-
Zoetis (ZTS) Announces $6B Share Buyback
-
BTIG Starts Zoetis Inc. (ZTS) at Buy
-
JPMorgan Pounding Table on Zoetis Inc. (ZTS): 'Remains Our Favorite Idea in the Space'

